VolitionRx Secures Up to $1.9 Million in Direct Offering

VolitionRx Secures Up to $1.9 Million in Direct Offering

Up to $1.9 million upfront with an additional $2.7 million in potential proceeds from the warrants.

VolitionRx Limited (NYSE AMERICAN: VNRX) is a global leader in epigenetics, and they have recently entered into definitive agreements for a registered direct offering. This announcement comes with the commitment to issue 445,648 shares of common stock priced at $0.5722 per share to various directors and executive officers of the company, known as the Insiders. Moreover, 2,857,389 shares are being offered to other investors, along with accompanying warrants designed to further enhance potential funding.

Investors will find that the offering price for each common stock plus the accompanying warrants is also set at $0.5722 per share. The warrants come in two types: Form A warrants allow the purchase of up to 2,857,389 shares, while Form B warrants permit purchasing up to 1,428,693 shares of common stock. The exercise prices for the A and B warrants are $0.5722 and $0.71525, respectively, and both types are immediately exercisable, expiring five years from issuance.

Notably, the company has opted to sell its securities directly to investors without utilizing an intermediary or placement agent for this offering. Following the close of transactions, expected to occur soon, VolitionRx anticipates generating up to $1.9 million in gross proceeds. This figure is calculated before factoring in estimated expenses connected to the offering. Should the warrants be fully exercised, the potential proceeds could rise significantly, adding around $2.7 million.

VolitionRx plans to allocate these funds strategically to advance their research initiatives and clinical studies. They are focused on enhancing product development and commercialization while also covering general operational costs.

The current offering falls under a shelf registration statement on Form S-3, filed with the Securities and Exchange Commission (SEC). The registration process is crucial as it authorizes the company to offer and sell securities under pre-defined terms over a period. Investors will be able to access a prospectus supplement detailing the offering once it is filed with the SEC.

This approach aligns with Volition's commitment to transparency and regulatory compliance, ensuring that investors are well-informed about the nature of the offerings being executed.

About Volition

VolitionRx is passionately dedicated to pioneering advancements in the field of epigenetics aimed at improving health outcomes. The company focuses on developing innovative blood tests designed to diagnose and monitor various diseases, including several forms of cancer and related conditions.

With a research base in Belgium and additional offices spanning the globe, VolitionRx is committed to sustainability and enhancing patient care through early detection technologies. Their products promise to provide a dual benefit—extending patient life expectancy while enriching life quality.

Media Contacts

For media inquiries, the key contacts are available for further engagement and dialogue. Reach out for discussions about advancements in epigenetics, product launches, or company news.

Frequently Asked Questions

What is the purpose of VolitionRx's recent offering?

The recent offering aims to raise funds for research, development, clinical studies, and product commercialization.

How much is VolitionRx aiming to raise?

VolitionRx seeks to raise approximately $1.9 million initially, with the potential for an additional $2.7 million through the exercise of warrants.

What are the types of warrants involved in this offering?

There are two types of warrants: Form A allows for the purchase of common shares at $0.5722, and Form B allows for purchasing at $0.71525.

Who are the intended recipients of this offering?

This offering targets both insiders of the company and external investors interested in VolitionRx's growth.

What is VolitionRx's primary focus in its operations?

VolitionRx is focused on developing blood tests for the early detection and monitoring of diseases, especially cancer.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.